Although allogeneic transplantation can be curative for patients with sickle cell disease, the toxicity of conditioning regimens has precluded its use in adults with significant end-organ damage. Newer conditioning regimens have been developed that are less toxic and that may broaden the applicability of allogeneic transplantation in this disorder. We report two adults with end-stage sickle cell disease, who underwent allogeneic transplantation from an HLA-identical sibling donor after conditioning with fludarabine/melphalan and ATG. Both patients had been extensively transfused and one had multiple RBC antibodies. One of the patients also had end-stage renal disease, and was dialysis dependent. Engraftment occurred promptly in both patients. Both achieved 100% donor chimerism and both were free of pain crises after transplant. The first patient died of a respiratory failure related to chronic graft-versushost disease (GVHD) on day 335 after transplantation. The second patient developed severe gastro-intestinal GVHD and TTP and died on day 147 after transplantation. Conditioning with fludarabine/melphalan and ATG followed by allogeneic stem cell transplantation resulted in prompt and reliable engraftment in adults with end-stage sickle cell disease. The incidence of severe GVHD was unacceptably high and may be related to the ethnicity of the patients or to the inflammatory state associated with pre-existing sickle cell disease. Bone Marrow Transplantation (2000) 26, 445-449.
expectancy for patients with sickle cell disease in the US is currently between 42 and 46 years, 5 and mortality in childhood and adolescence can be almost completely prevented by simple and inexpensive interventions. 3 On the other hand, in adulthood, sickle cell disease becomes increasingly more life-threatening, and among adults, patients at higher risk can be identified by the degree of end-organ damage. 5 However, end-organ damage which predicts for mortality from sickle cell disease also constitutes a major risk factor for treatment-related mortality after allogeneic transplantation. Paradoxically, those patients with sickle cell disease who have most to gain from transplantation, are usually not considered appropriate candidates.
The availability of immunosuppressive agents devoid of medullary or extramedullary toxicity, may provide the opportunity to develop conditioning regimens that are more tolerable and that can be used in older patients and those with more advanced disease.
6-8 Here, we report the cases of two adults with sickle cell disease who underwent allogeneic transplant from matched sibling donors using an attenuated conditioning regimen.
Case report

Patient 1
A 40-year-old patient who had been diagnosed with sickle cell disease at the age of 2 was referred for consideration of allogeneic stem cell transplantation. She had suffered multiple complications including repeated episodes of pain crisis, multiple transfusions, the development of transfusion-related red blood cell antibodies and splenic sequestration requiring splenectomy. At the age of 38 she developed renal failure due to sickle cell disease and was started on peritoneal dialysis. She was also maintained on hydroxyurea and erythropoietin. Her sister volunteered to serve as donor for a living related kidney transplant. During screening studies, the sister was found to be HLA-identical and to have a normal hemoglobin electrophoresis. Thereupon, an allogeneic transplantation was considered in order to correct the underlying hematologic disorder and as an attempt to induce tolerance for a subsequent renal allograft.
An extensive pre-transplant work-up was performed. There was a 25% decrease in pulmonary diffusion capacity. Serum ferritin was 740 ng/ml and liver biopsy showed focal lobular chronic inflammation, without extensive fibrosis. Cardiac function was well preserved. Magnetic resonance imaging of the brain showed scattered foci of abnormally increased signal throughout the brain, consistent with small vessel disease. Magnetic resonance angiography of the cranial vessels showed ischemic areas in both cerebral hemispheres. There was mild irregularity of the superior cerebellar arteries, but no abnormalities of the large cerebral vessels was demonstrated. No antibodies against hepatitis B, HCV and HIV were detected, but anti-CMV IgG was present. Panel reactive antibody (PRA) was 100% positive and the patient's serum contained antibodies against red blood cell antigens of types C, E, N, K, FYA and s. After an extensive search, 18 units of compatible red blood cells were identified and stored. The patient underwent a back-up harvest of autologous G-CSF-mobilized stem cells. In preparation for allogeneic transplantation peritoneal dialysis was discontinued and hemodialysis initiated.
Approval was obtained from the institutional review board to proceed with allogeneic transplantation and written informed consent was obtained from the patient. Conditioning consisted of ATG 30 mg/kg for 4 consecutive days (day −5 to day −2), fludarabine 30 mg/m 2 i.v. for 4 consecutive days (day −5 to day −2) and melphalan 140 mg/m 2 i.v. on day −1. The patient underwent hemodialysis on day −5, day −3 and day −1 after chemotherapy was administered. On day 0, the patient received an infusion of cryopreserved G-CSF-mobilized donor stem cells. GVHD prophylaxis consisted of daily tacrolimus and methotrexate 5 mg/m 2 given on days 1, 3 and 6. 9,10 Leucovorin rescue was given 24 h after methotrexate and hemodialysis was performed 24 h after each dose of methotrexate.
11 Filgrastim 5 g/kg s.c. was administered daily from day 7 until recovery of the WBC to Ͼ10 × 10 9 /l. CMV viremia was monitored by weekly PCR testing of the peripheral blood, and ganciclovir treatment instituted upon PCR positivity. Otherwise, supportive care was as previously published.
12,13
Her WBC decreased to less than 0.1 × 10 9 /l by day 5 and recovered by day 10. The platelet count also decreased to less than 40 × 10 9 /l by day 5. The patient became transfusion dependent for packed cells and platelets. Platelet transfusions were mostly directed donations from her HLAcompatible sibling. The platelet count recovered to more than 50 000 by day 33. Immediate post-transplant complications included a short period of fluid overload and tachycardia that required admission to the intensive care unit for approximately 48 h. Subsequently, she developed grade II acute GVHD involving the skin only, which was controlled with topical steroids. A planned kidney transplant on day 100 after the transplant had to be postponed because of pregnancy of the donor.
Hemoglobin was in the range of 8 to 11 g/dl from approximately day 50 after transplantation and the patient did not require erythropoietin. White blood cell counts and platelet counts also recovered. Blood smears did not show sickle cells or Howell-Jolly bodies and hemoglobin electrophoresis consistently showed the absence of sickle hemoglobin. Peripheral blood lymphocyte subsets were analyzed by PCR for microsatellite alleles to determine donor vs recipient origin. All detectable host monocytes, T and B cells were donor in origin by day 14, (sensitivity 1%) and when repeated approximately every 2 months, this profile remained constant. Post transplant, the PRA antibody panel had normalized and red blood cell antibodies could no longer be detected in the blood from 6 months after transplantation onwards and despite repeated challenge with transfusions.
14 The patient had no further pain crisis. On day 140 the patient developed an interstitial pneumonia that did not respond to i.v. antibiotics. Open lung biopsy revealed an interstitial lymphoid infiltrate consistent with either a viral infection or chronic GVHD. All cultures were negative. The patient responded rapidly to steroid therapy. On day 182, she suffered an upper GI bleed, presumably as a consequence of the steroid therapy. Subsequent to the GI bleed, steroids were tapered rapidly which led to worsening of GVHD. The subsequent course was characterized by repeated GI bleeds requiring transfusion, progressive worsening of pulmonary function and fluid overload due to non-compliance with dialysis. The patient expired from respiratory failure on day 355 after transplantation. An autopsy was not performed.
Patient 2
The second patient was a 56-year-old woman with SC disease. She had suffered frequent and debilitating pain crises, osteonecrosis, proliferative retinitis and pulmonary embolus. She had been extensively transfused but had not developed red blood cell antibodies. An HLA-identical sister with Hgb-S trait was identified.
An extensive pre-transplant work-up was performed. A 22% decrease in pulmonary diffusion capacity was found. Liver function was normal and serum ferritin was 142 ng/dl. Liver biopsy was not performed. Liver-spleen scan showed mild hepatomegaly and complete absence of the spleen. Cardiac and renal function were well preserved. Magnetic resonance imaging of the brain showed a few abnormal high signal foci in the left frontal lobe on T2-weighted images. Magnetic resonance angiography of the cranial vessels was normal. No antibodies against hepatitis B, HCV and HIV were detected, but anti-CMV IgG was present.
The patient underwent a back-up harvest of autologous G-CSF-mobilized stem cells. Conditioning and GVHD prophylaxis were identical to those used in the first patient. The patient's WBC decreased to less than 0.1 × 10 9 /l by day 4 and recovered by day 12. The platelet count decreased to less than 40 × 10 9 /l by day 7. The patient became transfusion dependent for packed cells and platelets. The platelet count recovered to more than 50 000 by day 16. Immediate post-transplant complications were minimal. Hemoglobin electrophoresis on day 30 revealed 1% residual HgbC and 10% HgBS. Subsequent electrophoreses on day 50 and day 120 did not show any residual Hgb C and less than 30% Hgb S. Peripheral blood lymphocyte subsets were analyzed by PCR for microsatellite alleles on day 30, day 50 and day 120. One hundred percent donor engraftment was shown. The patient had no further pain crisis. On day 23 she developed abdominal pain and diarrhea. Endoscopy revealed acute GVHD that was treated with high-dose steroids. On day 36 she developed a TTP-like syndrome with thrombocytopenia and mental status changes that was treated with plasma exchange and plasma infusions. Despite initial improvement, gastro-intestinal GVHD recurred. The patient responded transiently to ATG, but ultimately developed grade III GVHD of the liver and had to be maintained on high doses of steroids. Ultimately she developed cerebral infiltrates, presumably due to infection and she expired on day 142 after transplantation. An autopsy was not performed.
Discussion
Allogeneic bone marrow transplantation from HLA-identical siblings has been curative in children with sickle cell disease. In children with end-organ damage or 'advanced' sickle cell disease, the reported graft rejection rates and treatment-related mortality are approximately 10% each. In addition, approximately 10% of children develop extensive chronic GVHD. In adults, it can be anticipated that the complication rate will be higher, because of the generally increased risk of transplantation in older patients, the higher exposure to transfusions and the more severe degree of endorgan damage. Few adults with sickle cell disease have undergone transplantation, but in thalassemia, a higher morbidity and mortality has been observed after allogeneic transplantation for adults. 15 On the other hand, sickle cell disease is much more debilitating and carries a much worse prognosis in adults. A survey performed at our institution indicated that a substantial fraction of adults are interested in a curative approach, even if it entails considerable risk. 16 Prompted by the development of novel conditioning regimens that are potentially less toxic, we developed a pilot study of matched sibling transplantation for adults with sickle cell disease.
The regimen was based on the immunosuppressive properties of fludarabine, a nucleoside analog, 6-8 combined with melphalan and ATG which add further immunosuppression. 17, 18 Based on the preliminary results obtained with a similar regimen in elderly leukemic patients, 6 we hoped that early toxicity might be reduced. In addition, long-term side-effects on cardiac and pulmonary function or on fertility may also be avoided. 18, 19 We used G-CSFstimulated allogeneic PBSC as a source of donor stem cells because they lead to prompt and reliable engraftment and to improved survival in patients with advanced hematologic malignancies. 20, 21 To prevent GVHD a combination of tacrolimus and low-dose methotrexate was used. 20, 22 Because busulfan was not used in the conditioning, anticonvulsant therapy was not routinely administered.
Several conclusions emerge from our results, relating to engraftment, toxicity and GVHD. The prompt and durable engraftment that occurred in both patients is encouraging and may indicate that this regimen is adequately immunoBone Marrow Transplantation suppressive even in heavily transfused patients. Graft rejection has been a concern in children with sickle cell disease or thalassemia undergoing allogeneic transplantation and has been attributed to allo-immunization in heavily transfused patients. 1 With fludarabine and melphalan, complete and sustained engraftment as well as 100% donor chimerism have been observed in the majority of patients treated. 23 The addition of ATG is likely to have further facilitated engraftment.
Duration of neutropenia was short and acute toxicity in both patients was limited. The fact that this regimen could be safely administered in a patient undergoing dialysis, is a further illustration of the reduced toxicity of fludarabinebased conditioning regimens. GVHD prophylaxis was possible by careful monitoring of tacrolimus levels. Methotrexate toxicity was prevented by leucovorin rescue and frequent hemodialysis.
11
Unfortunately both patients developed severe complications that were in each case related to GVHD. In the first patient, acute GVHD was controllable with steroids, but subsequently a severe and partially steroid-responsive pulmonary syndrome occurred that was most consistent with pulmonary GVHD and that was ultimately responsible for the patient's demise. In the second patient, severe acute GVHD combined with TTP caused the patient's death.
This experience, although limited, indicates an incidence of severe GVHD of at least 30% (90% CI: 31-100%). Others have reported a high incidence of severe GVHD in African-Americans undergoing allogeneic transplantation, and have speculated that a high degree of polymorphism in minor histocompatibility antigens or differences in pharmacokinetics of anti-GVHD drugs may be responsible. 24, 25 An alternative explanation may pertain to the underlying sickle cell syndrome. Patients with sickle cell disease have high circulating levels of inflammatory cytokines, especially endothelin-1 and TNF alpha. 26 These are inflammatory cytokines which are likely to contribute to the onset of GVHD syndromes 27 and may explain why patients with sickle cell disease may be at higher risk for GVHD than are other patients. Whatever the etiology, our observations indicate that GVHD constitutes a major risk in adults undergong allogeneic stem cell transplantation sickle cell disease. GVHD is obviously a completely unacceptable side-effect in the treatment of an illness where graftversus-tumor effects are irrelevant.
Different modifications of this protocol could be considered. One would be to substitute bone marrow for PBSC. This option inflicts more morbidity on donors, 28 and has been shown to be associated with decreased survival in patients with advanced hematologic malignancies. 21 Hence, it is also likely to result in increased toxicity in patients with sickle cell disease. Another approach would be to further reduce the conditioning, in the hope of achieving a durable state of mixed chimerism which is likely to be associated with a decreased incidence of GVHD, and may result in durable control of symptoms. 29 Such an approach may, however, carry a higher risk of graft failure. A third approach may involve using T cell depletion of blood stem cells. In patients with hematological malignancies, T celldepleted stem cell transplantation was associated with a very low incidence of both acute and chronic GVHD and reliable engraftment. 30 We are currently pursuing this approach in a new pilot study.
In conclusion, our experience indicates that fludarabine/melphalan/ATG results in durable engraftment in adults with sickle cell disease undergoing allogeneic stem cell transplantation. Acute toxicity is acceptable, but severe GVHD represents a major obstacle to the success of transplantation. If the incidence of GVHD can be improved without affecting engraftment, the remaining obstacle to widespread use of allogeneic transplantation in sickle cell disease, the lack of compatible donors, 31 may some day be overcome by the more effective use of alternative donor sources.
